Both gut local and systemic IDO1 overexpression in body were supported by significantly increased IDO1 activity in active IBD patients and by negative association between serum tryptophan levels and C-reactive protein expression compared with non-active IBD patients 60. Here, IDO1 is linked to irritable bowel syndrome.